CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges

Xiaomin Zhang1,2, Lingling Zhu3, Hui Zhang4, Shanshan Chen3 and Yang Xiao2,5*

1 Department of Hematology, Jinshazhou Hospital of Guangzhou University of Chinese Medicine, Guangzhou, China, 2 Institute of Clinical Medicine College, Guangzhou University of Chinese Medicine, Guangzhou, China, 3 Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, China, 4 School of Medicine, Jishou University, Jishou, China, 5 Department of Hematology, Shenzhen Qianhai Shekou Pilot Free Trade Zone Hospital, Shenzhen, China

Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T cell therapy, and numerous novel therapeutic targets are being explored. However, the adverse events related to CAR-T cell therapy might be serious or even life-threatening, such as cytokine release syndrome (CRS), CAR-T-cell-related encephalopathy syndrome (CRES), infections, cytopenia, and CRS-related coagulopathy. In addition, due to antigen escape, the limited CAR-T cell persistence, and immunosuppressive tumor microenvironment, a considerable proportion of patients relapse after CAR-T cell therapy. Thus, in this review, we focus on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets, CAR-T related toxicities, and resistance to CAR-T cell therapy, and provide some practical recommendations.

Keywords: CAR-T cell, hematological malignancies, CAR-T related toxicities, antigen escape, immunosuppressive tumor microenvironment, combinatorial therapy

INTRODUCTION

Traditionally, the treatment of hematological malignancies mainly includes chemotherapy, radiotherapy, and hematopoietic stem cell transplantation (HSCT). However, with advances in tumor immunology, immune targeted therapy, such as monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and chimeric antigen receptor T (CAR-T) cell therapy, has opened a new avenue for the treatment of malignancies. In particular, CAR-T cell therapy has revolutionized the treatment of hematological malignancies and achieved unprecedented responses in recent years, especially in relapsed/refractory (R/R) B-cell acute lymphocytic leukemia (B-ALL), non-Hodgkin lymphoma (NHL), and multiple myeloma (MM). At present, there are six CAR-T cell products approved by the US Food and Drug Administration (FDA) for the treatment of R/R B cell malignancies, including tisagenlecleucel (Kymriah; Novartis), axicabtagene ciloleucel (Yescarta; Gilead), brexucabtagene autoleucel (Tecartus; Gilead), lisocabtagene maraleucel (Breyanzi; Bristol Myers Squibb), idecabtagene vicleucel (Abecma; Bristol Myers
Squibb and Bluebird Bio), and ciltacabtagene autoleucel (Carvykti; Legend and Janssen), which target the most common target antigens CD19 and B cell maturation antigen (BCMA) (Table 1 landmark clinical trials). In addition, there are a considerable number of novel targets which are being explored.

However, despite the remarkable breakthrough of CAR-T therapy in B cell malignancies, severe toxicities associated with CAR-T cell therapy may compromise its efficacy and could even progress into life-threatening conditions, such as multiple organ dysfunction, sepsis, and disseminated intravascular coagulation (DIC). Cytokine release syndrome (CRS) is the most common complication, which is a systemic inflammatory response induced by the overactivation of CAR-T cells and endogenous immune cells, such as macrophages and dendritic cells. Its manifestations are diverse and partially similar with infections. Moreover, severe CRS is correlated with the increased risk of CAR-T-cell-related encephalopathy syndrome (CRES) and coagulopathy (9). Thus, clarifying their underlying mechanisms could facilitate the prevention and management of these adverse events. In addition, the resistance after CAR T-cell therapy cannot be ignored.

Thus, this review aims to introduce the advances and challenges in CAR-T cell therapy, such as attractive therapeutic targets, toxicities related to CAR-T cell therapy, and resistance to CAR-T cell therapy, and explore their underlying mechanisms and effective treatment strategies in order to facilitate the application and management of CAR-T cell therapy.

**OVERVIEW OF CAR-T CELL THERAPY**

To manufacture CAR-T cells, T cells are collected from peripheral blood of patients or donors and then genetically engineered in vitro to express chimeric antigen receptor (CAR). Thus, CAR-T cells recognize specific surface antigens on tumor cells without antigen processing and presentation, which indicates that antigen recognition by CAR-T cells is independently of major histocompatibility complex (MHC) restriction. After genetic modifications, they undergo extensive expansion in vitro. Then the patients receive lymphodepleting chemotherapy to make room for these adoptive CAR-T cells, and subsequently these genetically engineered CAR-T cells are re-infused into the patients. These CAR-T cells specifically recognize target antigens and rapidly proliferate to exert anti-tumor effects in vivo.

The CAR structure consists of an extracellular antigen-recognition domain, a transmembrane domain, and an intracellular signaling domain. The extracellular domain, a single-chain variable fragment (scFv), is able to specifically recognize tumor surface antigens. Typically, tumor antigens are categorized into tumor-associated antigens (TAAs) and tumor specific antigens (TSAs), and most of them are TAAs. Once TAAs are identified by scFv, CAR-T cells are activated and transmit activation signals to the intracellular domain. The first-generation CAR construct contains an antigen-recognition domain scFv and an intracellular CD3ζ activation domain. Due to the absence of costimulatory signals, they exhibit the limited proliferative capacity and anti-tumor effects. The second-generation CAR construct adds a costimulatory domain, such as CD28, 4-1BB, OX40, or ICOS, which enables itself to possess the better proliferative capacity and release more cytokines. Currently, these commercial CAR-T cell products both utilize the second-generation CAR construct. The third-generation CAR construct encompasses two distinct costimulatory molecules, such as CD28 and 4-1BB. The fourth-generation CAR construct, also named TRUCK or armored CAR, is additionally modified to secrete cytokines or express suicide genes, such as IL-7, IL-12, IL-15, IL-21, and iCaspaš-9.
The fourth-generation CAR-T cells may be more effective in eliminating tumor cells by activating the endogenous immune responses. However, the characteristics of fourth-generation CAR-T cells are largely unknown. In addition, the 2020 American Society of Hematology (ASH) annual meeting announced two studies about FasT CAR-T cells, including CD19-CD22 FasT dual-targeting CAR-T cells (GC022F) in B-ALL patients and BCMA-CD19 FasT dual-targeting CAR-T cells (GC012F) in R/R MM patients (12, 13). These FasT CAR-T products were manufactured in 24 to 36 hours and showed superior efficacy in preliminary studies, indicating that they might be more suitable for rapidly progressive B cell malignancies.

At present, all commercial CAR-T cell products are manufactured using autologous T lymphocytes, but high manufacturing costs, relatively longer manufacturing cycle, and decreased number and function of lymphocytes after multiline chemotherapies have restricted their further application. However, it seems that universal CAR-T (UCAR-T) cells which are derived from healthy donors are able to overcome these limitations. The large-scale production of UCAR-T cells makes them “off-the-shelf” products, which could reduce manufacturing costs and increase their accessibility. Unfortunately, these allogeneic UCAR-T cells could induce graft versus host disease (GVHD) (14). Furthermore, the host immune system is able to reject these donor-derived UCAR-T cells and impairs their persistence. In addition, due to the excellent natural killing functions of NK cells and their abundant sources, such as NK92 cell line, cord blood, peripheral blood, and induced pluripotent stem cells, as well as no induction of GVHD, CAR-NK cells are currently being explored (15).

**ATTRACTION TARGETS FOR CAR-T CELL THERAPY IN HEMATOLOGICAL MALIGNANCIES**

Currently, CD19 and BCMA are the most common targets in CAR-T cell therapy. Although anti-CD19 CAR-T cell therapy and anti-BCMA CAR-T cell therapy have achieved outstanding outcomes in B cell malignancies, relapse after CAR-T cell therapy is frequently observed. In addition, due to the antigenic heterogeneity of acute myeloid leukemia (AML) as well as the lack of CD19 expression in Hodgkin lymphoma (HL) and T cell malignancies, a number of potential targets are currently being investigated (Figure 2).

**Targets for CAR-T Cell Therapy in B Cell Lymphoblastic Leukemia/Lymphoma**

The CD19 is one of the most important target antigens in B cell malignancies, including B-ALL and NHL. In recent years, anti-CD19 CAR-T cell therapy has achieved rapid and durable responses in patients with R/R B-ALL and NHL (1–6, 16), and has dramatically altered the therapeutic landscape of B cell malignancies. Until now, four anti-CD19 CAR-T cell products have been approved by FDA for the treatment of R/R B-ALL and NHL (17). Despite the outstanding clinical results of anti-CD19 CAR-T therapy, CD19 antigen loss is frequently observed (18). Thus, the alternative targets for CAR-T cell therapy in R/R B-ALL and NHL have been explored.

CD20 is overexpressed in over 90% of B cell lymphomas and identified as an attractive target for CD20 positive B cell lymphomas, and the anti-CD20 monoclonal antibody rituximab has showed the excellent effect on NHL over the past few years. In an early clinical trial, the overall response rate (ORR) of anti-CD20...
CAR-T cell therapy in DLBCL patients was 86% (19). In subsequent phase 1 and 2 trials, the anti-CD20 CAR-T cells were administrated to 17 R/R NHL patients, and 54.5% of patients achieved complete remissions (CRs) and 12 patients remained in remission with a median follow-up of 20 months (20). To prevent antigen escape, the combination of anti-CD19 and anti-CD20 CAR-T cells for the treatment of R/R DLBCL was investigated, and this combinational therapy was demonstrated to be safe and feasible (21). CD22 is highly expressed on most B cell malignancies, including B-ALL and DLBCL (22, 23). In particular, it is restrictively expressed on normal B cells and not expressed on hematopoietic stem cells, so it is an ideal target for CAR-T cell therapy in R/R B-ALL and DLBCL. In several clinical trials, the anti-CD22 CAR-T cell therapy has shown excellent efficacy in R/R B-ALL and R/R DLBCL patients who have failed in previous anti-CD19 CAR-T cell therapy (24–26). In addition, the humanized anti-CD22 CAR-T cells exhibit potent activity against leukemia cells with low CD22 expression (27).

**Targets for CAR-T Cell Therapy in T Cell Lymphoblastic Leukemia/Lymphoma**

Patients with R/R T-cell acute lymphoblastic leukemia (T-ALL) and T cell lymphomas often have poor prognosis. Compared with the outstanding clinical outcomes of anti-CD19 CAR-T cell therapy in B cell malignancies, the efficacy and safety of CAR-T cell therapy in T cell malignancies are largely unknown and under investigation. CD7 is highly expressed in 95% of T-ALL patients and represents a desirable target for the treatment of T-ALL (28). In an open-label and single-arm clinical trial, 2 R/R T-ALL patients were treated with allogeneic anti-CD7 CAR-T cell therapy. One patient remained in remission for over 1 year, while the other relapsed 48 days after CAR-T cell infusion (28). In another phase I clinical trial, 20 R/R T-ALL patients received donor-derived anti-CD7 CAR-T cell infusion, and 90% of participants achieved CRs (29). In addition, a case study reported that an 11-year-old T-ALL patient who didn’t respond to induction failure was treated with autologous anti-CD7 CAR-T cell therapy, and he achieved remission on day 17 and subsequently underwent HSCT (30). CD5 is expressed in approximately 85% of T cell malignancies, such as T-cell lymphoblastic lymphoma (T-LBL) and peripheral T-cell lymphoma (PTCL). A recent study has demonstrated that anti-CD5 CAR-T cells effectively eliminated malignant T cells (31). In a phase I clinical trial, a refractory T-LBL patient with central nervous system (CNS) infiltration received the anti-CD5 CAR-T cell therapy and achieved CR within 4 weeks (32). Additionally, anti-CD4 CAR-T cells showed superior activity against T cell malignancies in preclinical studies (33). However, all three targets CD4, CD5 and CD7 are expressed on normal T cells, so targeting them may result in the depletion of normal T cells.
and the fratricide of CAR-T cells (34). Malignant T cells express T cell receptor β-chain constant domains 1 (TRBC1), so anti-TRBC1 CAR-T cells are able to selectively eliminate TRBC1-positive malignant T cells. Importantly, it could retain a majority of normal T cells in vivo (35). CD99 is highly expressed in newly diagnosed T-ALL patients, and it represents a novel target for T-ALL (36). Furthermore, chemokine receptor CCR9 is expressed in over 70% of T-ALL patients, and only on less than 5% of normal T cells. In addition, it is correlated with multidrug resistance and poor prognosis. Thus, it represents an ideal target for CCR9 positive T-ALL. In preclinical studies, anti-CCR9 CAR-T cells exhibited potent anti-leukemic activity and were resistant to fratricide (37).

In addition, CD30 is highly expressed in anaplastic large-cell lymphoma (ALCL) and is variably expressed in PTCL subtypes. In particular, CD30 is restrictively expressed on normal T cells. Thus, CD30 is an ideal target for these lymphoma subtypes, and the anti-CD30 antibody-drug conjugate brentuximab vedotin (BV) has shown a high response rate in newly diagnosed PTCL patients (38, 39). Given the encouraging clinical efficacy of BV, the anti-CD30 CAR-T cells were developed and exhibited remarkable cytotoxicity against CD30 positive lymphomas in preclinical studies (40, 41).

**Targets for CAR-T Cell Therapy in Hodgkin Lymphoma**

Anti-CD19 CAR-T cell therapy has shown excellent results in R/R B cell NHL. However, HL lacks the expression of CD19. Interestingly, CD30 is universally expressed in classical HL. Currently, several clinical trials have been carried out to evaluate the safety and efficacy of anti-CD30 CAR-T cell therapy in R/R HL (42–45). In a clinical trial from China, 5 of 6 HL patients achieved CRs after the infusion of the third-generation anti-CD30 CAR-T cells, and the long-term remission lasted over 24 months in 3 patients (45). In another phase 1/2 clinical trial, 27 patients were treated with the anti-CD30 CAR-T cells and 67% of patients achieved CRs within 6 weeks, but 63% of patients experienced disease progression with a median follow-up of 9.5 months (46). In addition, the expression of CD30 in HL was down-regulated after anti-CD30 CAR-T cell therapy (47).

**Targets for CAR-T Cell Therapy in Acute Myeloid Leukemia**

AML is the most common acute adult leukemia. Unfortunately, due to antigenic heterogeneity, the CAR-T cell therapy in AML has not achieved the same success as ALL. Recently, CD123, CD33, CD38, CD70, C-type lectin-like molecule-1 (CLL-1), leukocyte immunoglobulin-like receptor-B4 (LILRB4), FMS-like tyrosine kinase 3 (FLT3) and sialic acid-binding immunoglobulin-like lectin 6 (Siglec-6) have been explored. CD123 and CD33 are highly expressed on leukemic stem cells in over 80% of AML patients, but they are expressed on hematopoietic stem cells as well (48). Accordingly, targeting them could increase the risk of long-term myelosuppression (49). To decrease hematological toxicity, a rapidly switchable universal anti-CD123 CAR-T cells were prepared (50, 51). In a small study, 3 R/R AML patients were treated with this universal anti-CD123 CAR-T cells, and all of them achieved a clinical response with the rapid hematologic recovery after the withdrawal of switch-mediated co-stimulation (52). In another phase 1 trial, 3 R/R AML patients received autologous anti-CD33 CAR-T cell infusion. Unfortunately, all of them died from disease progression (53). CD38 is expressed on most AML blast cells, and anti-CD38 CAR-T cell therapy was demonstrated to be effective in relapsed AML after allogeneic HSCT (54). CLL-1, which has been identified as an myeloid cell surface marker, is overexpressed on leukemia stem cells (55). Importantly, it is absent on hematopoietic stem cells. The CLL-1-targeted CAR-T cells specifically eliminated CLL-1 positive leukemia in preclinical studies (56, 57). CD70 is expressed on AML blasts but not on normal myeloid cells, making it a promising target for the treatment of AML (58, 59). Currently, the safety and efficacy of anti-CD70 CAR-T cell therapy are under investigation. In addition, LILRB4 is highly expressed on mononuclear AML cells, and it is an attractive target for mononuclear AML (60). Siglec-6 is expressed in approximately 60% of AML patients and absent on normal hematopoietic stem and progenitor cells. In preclinical studies, Siglec-6 CAR-T cells effectively eliminated AML blasts in an AML mouse xenotransplantation model (61). Thus, it could serve as a well-validated target for CAR-T cell therapy in AML. In addition, nucleophosmin 1 (NPM1) mutations have been observed in 30%-35% of AML patients, and they are considered to be initiating mutations in leukemic cells. In preclinical mouse models, CAR-T cells targeting a nucleophosmin neoepitope which is presented by HLA-A2 exhibited potent specific anti-leukemia activity (62).

FLT3 is a transmembrane tyrosine kinase expressed on malignant blasts in approximately 30% of AML patients. FLT3 mutations include point mutations and an internal tandem duplication (ITD), and FLT3-ITD is correlated with poor prognosis. In preclinical studies, the FLT3-targeted CAR-T cells successfully eliminated FLT3 positive AML cells (63, 64), and the FLT3 inhibitor crenolanib promoted their anti-tumor effects (64). Unfortunately, FLT3 is also expressed on normal hematopoietic stem and progenitor cells, so the FLT3-targeted CAR-T cells may affect normal hematopoiesis (64, 65).

**Targets for CAR-T Cell Therapy in Multiple Myeloma**

MM remains an incurable plasma cell malignancy. With the application of novel agents, such as proteasome inhibitors, immunomodulatory drugs, and anti-CD38 monoclonal antibodies, MM patients have significantly improved survival outcomes (66). However, almost all MM patients inevitably relapse. BCMA is highly selectively expressed on malignant plasma cells, so it represents one of the most promising therapeutic targets for MM. At present, anti-BCMA CAR-T cell therapy has been demonstrated to be effective in R/R MM and achieved unprecedented responses (7, 8, 67–69), and two anti-BCMA CAR-T cell products, idecabtagene vicleucel and
cell therapy is effective in R/R MM patients with extramedullary complications, it is important to explore their underlying mechanisms. Therefore, new target antigens are required (74).

Currently, several potential target antigens have been investigated, such as CD38, CD138, CD229, SLAMF7, a proliferation-inducing ligand (APRIL), and G protein-coupled receptor, class C group 5 member D (GPRC5D). CD138 is highly expressed on MM cells and promote their survival and proliferation. In a preclinical study, anti-CD138 CAR-T cells effectively eliminated MM cells (75). In a small clinical trial, 5 patients received anti-CD138 CAR-T cell therapy, and 4 of them had a clinical response and remained stable for at least three months (76). CD38 is not only highly expressed on MM cells, but also expressed on hematopoietic cells and activated lymphocytes (77). Unfortunately, although the anti-CD38 CAR-T cells exhibited significant anti-tumor effects in mouse models, they impaired normal hematopoietic cells and lymphocytes (78). Clinically, CD38 is frequently combined with other targets, such as BCMA and CD138, to produce bispecific CAR-T cells, thereby reducing the risk of antigen escape (79, 80). CD229 is a surface antigen highly expressed on MM cells (81). The anti-CD229 CAR-T cells effectively eliminated MM cells in preclinical studies (82). SLAMF7, also known as CS1, is highly expressed in over 95% of MM patients. Similar to CD38, SLAMF7 is also expressed on normal lymphocytes, including activated T cells, NK cells, and B cells (83). Thus, SLAMF7 CAR-T cells could kill normal lymphocytes and increase the risk of CAR-T cell fratricide (84). Currently, the clinical trial of SLAMF7 CAR-T cells is ongoing (85). APRIL is a natural ligand which could directly bind to BCMA and transmembrane activator and CAML interactor (TACI). Thus, APRIL-targeted CAR-T cells recognize both BCMA and TACI expressed on MM cells, which may decrease the risk of antigen escape (86), and preserving its trimeric conformation could improve the anti-tumor activities (87). In addition, TGPRC5D is expressed on more than 50% of CD138 positive malignant plasma cells in bone marrow of MM patients, which also represents a potential target for the treatment of MM (88).

TOXICITIES RELATED TO CAR-T CELL THERAPY AND THEIR UNDERLYING MECHANISMS

Although CAR-T cell therapy has achieved great success in hematological malignancies, the adverse events related to CAR-T cell therapy remain to be a major challenge, such as CRS, CRES, B cell aplasia, cytopenia, and CRS-related coagulopathy. Without active and effective interventions, these complications might be life-threatening. In order to effectively manage these complications, it is important to explore their underlying mechanisms and recognize them in early stages.

Cytokine Release Syndrome

CRS is one of the most common toxicities of CAR-T cell therapy. The incidence of CRS depends on a variety of factors, including disease characteristics, CAR structure, tumor burden, and CAR-T cell doses (89). The clinical manifestations of CRS are diverse, but they are frequently characterized by fever, fatigue, myalgia, poor appetite, hypoxia, hypotension, and even organ dysfunction. If left untreated, it might rapidly progress into life-threatening conditions, such as hemodynamic instability and multiple organ dysfunction. However, the recent study revealed that the patients with ≥ grade 2 CRS had higher rates of remission and longer progression-free survival (PFS) compared with those with < grade 2 CRS, which indicates that appropriate CRS might facilitate the efficacy of CAR-T therapy (90). Because CRS are primarily mediated by IL-6, IL-6 receptor antagonist tocilizumab is mainly recommended to relieve the clinical symptoms of CRS. According to different CRS grading, different treatment regimens are adopted. The symptomatic treatment and the supportive treatment are indicated for grade 1 CRS. Tocilizumab and corticosteroids are recommended for grade 3 and 4 CRS as well as grade 2 CRS accompanied by severe symptoms. Moreover, IL-1 is another important cytokine involved in CRS and CRES, and IL-1 receptor antagonist anakinra has been demonstrated to ameliorate both CRS and CRES (91–95). Furthermore, GM-CSF deficiency or inhibition not only can alleviate CRS and CRES by inhibiting the local infiltration of myeloid cells and T cells, but also enhance the anti-tumor effects of CAR-T cells (96, 97). Besides, the severity of CRS is positively associated with the patient’s tumor burden (89). To reduce tumor burden, traditional chemotherapy and radiotherapy could serve as the effective bridging strategies before CAR-T cell infusion.

The detailed mechanisms of CRS remain incompletely understood. After recognizing target antigens, CAR-T cells are rapidly activated and secrete a large amount of granzyme, perforin, IFN-γ, and TNF-α. Perforin forms pores on tumor cell membrane and allows granzyme B to enter tumor cells. Granzyme B activates GSDME which is widely expressed on CD19 positive malignant B cells, resulting in tumor cell pyroptosis and the release of danger-associated molecular patterns (DAMPs), such as high-mobility group box 1 (HMGB1) (98–101). Then DAMPs recruit and activate endogenous innate immune cells, such as macrophages and dendritic cells, thereby amplifying inflammatory responses and increasing the release of cytokines, including IL-1β and IL-6. Currently, it has been demonstrated that macrophages and monocytes rather than CAR-T cells are the major sources of these cytokines and contribute to CRS (91, 92, 102, 103). In addition, the CD40 and CD40 ligand (CD40L) interactions between CAR-T cells and host antigen-presenting cells (APCs) as well as tumor cells also play an important role in immune activation and the release of cytokines (104–106). CD40 is expressed on multiple APCs, including B cells, macrophages, dendritic cells (DCs), and monocytes, and highly expressed in a variety of hematological malignancies, such as NHL, AML, MM (105–108). CD40L is highly expressed on activated T cells,
including CAR-T cells (104, 109). The contact-dependent CD40/CD40L interactions enhance the antigen presentation of APCs and CD40 positive malignancies and promote their secretion of cytokines, such as IL-1β, IL-6, and TNF-α (110, 111) (Figure 3).

In addition, because endothelial cells act as conditional innate immune cells and express CD40, the CD40/CD40L interactions also participate in the activation of endothelial cells. Since lymphoma lesions are mostly localized, CRS in lymphoma exhibits some distinct manifestations, such as local CRS, which is characterized by local redness, swelling, and heat. Then, CAR-T cells persistently expand and over-flow into the circulation, and experience redistribution as well as mediating tissue damage. Finally, inflammation subsides and the impaired tissues are gradually repaired (112). Thus, the early management of local CRS is helpful to reduce the occurrence of subsequent systemic CRS.

**CAR-T-Cell-Related Encephalopathy Syndrome**

CRES, also known as CAR-T cell-related neurotoxicity, is another common toxicity during CAR-T cell therapy. It usually occurs simultaneously with CRS or later than CRS. The manifestations of CRES include headache, dizziness, delirium, seizures and cerebral edema. Due to the lack of suitable animal models, the underlying pathological mechanisms of CRES are not fully understood. Severe CRS, high tumor burden, and excessive CAR-T cell expansion might be correlated with the increased risk of CRES. Currently, immune-mediated endothelial activation is a well-established mechanism involved in the occurrence of CRES (113–115).

Upon the recognition of target antigens, CAR-T cells rapidly proliferate and release multiple cytotoxic molecules, such as granzyme, perforin, IFN-γ, and TNF-α, and upregulate the expression of CD40L and Fas ligand (Fasl), and eventually induce pyroptosis and apoptosis of tumor cells. Besides, the CD40/CD40L interactions between tumor cells and CAR-T cells promote Fas-mediated apoptosis. Then the lysed tumor cells release large amounts of DAMPs, such as HMGB1, which could activate innate immune cells, including macrophages and dendritic cells, further amplifying inflammatory responses. In addition, the CD40/CD40L interactions participate in the activation of various immune cells, including T cells, B cells, macrophages, dendritic cells, and conditional innate immune cells such as endothelial cells. The activated CAR-T cells with the increased expression of CD40L could activate macrophages and endothelial cells and promote their production of pro-inflammatory cytokines in a CD40-dependent manner. The cytokines released from activated immune cells could bind to their receptors on endothelial cells and then mediate endothelial dysfunction, resulting in capillary leakage and the release of procoagulant factors.
targets for CAR-T cell therapy in B-ALL and lymphoma. BCMA, a plasma cell-selective protein, is highly expressed on MM cells as well as mature B cells and normal plasma cells. Thus, CD19-targeted, CD20-targeted and BCMA-targeted CAR T cells exhibit superior anti-tumor activity in B cell malignancies (1, 3, 67, 127), but they attack normal B cells as well, which could result in impaired humoral immunity, such as B cell aplasia and hypogammaglobulinemia (128–131). Moreover, lymphodepleting chemotherapy prior to CAR-T cell infusion could also impair host immunity. Due to impaired host immunity, these individuals are more susceptible to infections (132). It has been demonstrated that most of infection events occur during the first 30 days of CAR-T cell infusion, and the bacterial infection predominates, mainly including bloodstream infection and respiratory infection (133). In a phase 1/2 study, 31% of the patients who received the anti-CD19 CAR-T therapy experienced infections between day 31 and day 180 (134). Thus, the long term follow-up and the detection of gamma globulin levels might be helpful. To restore humoral immunity, immunoglobulin supplementation is essential for these immune-compromised individuals. In addition, the high-dose CAR-T cell infusion seems to be associated with the infections after CAR-T cell infusion (134, 135). Thus, CAR-T cells can be administered in a dose-escalation regimen. Furthermore, CAR-T cell therapy increases the risk of HBV reactivation in patients with resolved HBV infections due to persistent B-cell aplasia, so antiviral prophylaxis and regular monitoring of the virus are recommended (128, 136, 137). Unfortunately, with the application of CAR-T cell therapy in T cell malignancies, T cell aplasia might be observed because a majority of target antigens are co-expressed on normal T cells (34).

However, it is difficult to differentiate between CRS and infections due to the similar clinical manifestations, such as pyrexia and the elevated levels of pro-inflammatory cytokines and C-reactive protein (CRP). Moreover, CRS is likely to occur simultaneously with infections. In order to avoid the life-threatening infections during CAR-T cell therapy, the early recognition and management of infections is important. Nevertheless, it is usually not timely to identify the infection by blood culture (133). Thus, the detection of special biomarkers or the establishment of a prediction model for infection is critical. IL-6 is one of the key cytokines involved in the infection-induced cytokine storm and CAR-T cell therapy-induced CRS. Typically, the elevation of serum IL-6 associated with CRS occurs within 3 weeks after CAR-T cell infusion, so the “double peaks of IL-6” is identified as one of the characteristics of life-threatening infections. Compared with blood culture, it seems that employing the “double peaks of IL-6” pattern to predict the life-threatening infection is faster (135). When infection is suspected, empiric anti-infective treatment should be initiated immediately once blood and sputum samples are collected for the detection of pathogenic microorganisms, especially in neutropenic patients. In addition, Herpesvirus infections have been occasionally observed in several clinical trials (138–140). To prevent herpesvirus infections, it’s recommended that acyclovir 400 mg should be prophylactically administrated twice daily from lymphodepletion chemotherapy to at least 6 months post-CAR-T cell infusion (141).

**Cytopenia**

Cytopenia is frequently observed during CAR-T cell therapy and lasts for several days to months, including anemia, thrombocytopenia, and leukenopaenia, and the incidence of cytopenia range from 30% to 100% in clinical trials (2, 29, 72, 79, 142, 143). It has been demonstrated that cytopenia is associated with severe CRS (144–146). Under inflammatory conditions, CD40 is significantly up-regulated on granulocytic progenitor/precursor cells which also express low levels of CD40L, and the CD40/CD40L interactions between granulocytic progenitor/precursor cells significantly promote their own apoptosis (147). In addition, the pro-inflammatory cytokines, such as IL-1, TNF-α, and HMGB1, could suppress erythropoietin production (148, 149), and the activated macrophages could destroy erythrocytes (150). The limited hematopoietic capacity mediated by prior chemotherapy and HSCT might be involved in cytopenia as well (151–153). Furthermore, some target antigens are co-expressed on normal hematopoietic stem or progenitor cells, so CAR-T cells could directly mediate the destruction of hematopoietic cells (48, 49). Clinically, red blood cell and platelet transfusions and hematopoietic growth factors, such as granulocyte colony-stimulating factor (G-CSF) and thrombopoietin (TPO), as well as TPO receptor agonists and sirolimus, are able to ameliorate cytopenia (154, 155).

**CRS-related Coagulopathy**

As a newly identified toxicity, coagulopathy is frequently observed within 1 month after CAR-T cell infusion (156, 157). Its severity shows a positive correlation with CRS grade as well as the levels of IL-6 (9), so it’s also known as CRS-related coagulopathy. The recent studies have reported that the incidence of coagulopathy during CAR-T therapy is approximately 50% (9, 156). There are multiple abnormal coagulation parameters in patients with CRS-related coagulopathy, mainly characterized by the elevated levels of D-dimer, the increased fibrinogen degradation products, and the decreased levels of fibrinogen as well as the prolonged prothrombin time. The progress of CRS-related coagulopathy can be divided into three stages, including hypercoagulable stage, consumptive hypo-coagulable stage, and hyperfibrinolysis stage (9). At hypercoagulable stage, the patients mainly present with excessive micro-thrombosis, which can be treated with anticoagulant drugs, such as low-molecular-weight heparin. At consumptive hypo-coagulable stage, the individuals exhibit bleeding, accompanied by the decreased fibrinogen levels and the prolonged APTT and PT, so replacement treatment is required. At hyperfibrinolysis stage, the fibrinogen level is substantially decreased and the level of D-Dimer is significantly up-regulated. Once the fibrinogen level in plasma is lower than 1.5 g/L, the fibrinogen concentrate or cryoprecipitate replacement should be administered (Table 2).
TABLE 2 | Toxocities related to CAR-T cell therapy and effective solutions.

| Toxocities                                    | Manifestations                                                                 | Solutions                                                      | Reference |
|-----------------------------------------------|--------------------------------------------------------------------------------|-----------------------------------------------------------------|-----------|
| CRS                                           | grade 1 CRS: fever, fatigue, myalgia, nausea, and/or malaise                    | supportive care, tocilizumab, corticosteroids, and intensive care| (117)     |
| CRES                                          | grade 2 or higher CRS: fever, hypoxia, hypotension, and organ dysfunction        | tocilizumab, corticosteroids, and intensive care                 | (93, 95, 117) |
| B cell aplasia                                | hypogammaglobulinemia                                                           | immunoglobulin infusion, antiviral prophylaxis                  | (128, 136, 137, 141) |
| Cytopenia                                     | anemia                                                                          | acetaminophen, platelet transfusions, thrombopoietin, romiplostim| (154)     |
| CRS-related coagulopathy                      | hypercoagulable stage: extensive micro-thrombosis, normal/shortened APTT and PT | anticoagulant treatment combined with replacement treatment: low-molecular weight heparin | (9)       |
|                                               | consumptive hypo-coagulable stage: hemorrhage, decreased fibrinogen levels, and prolonged APTT and PT | anticoagulant treatment combined with replacement treatment: low-molecular weight heparin, fresh-frozen plasma, cryoprecipitate, fibrinogen concentrate | (9)       |
|                                               | Hyperfibrinolysis stage: hemorrhage, hypofibrinogenemia, significantly increased levels of D-Dimer and FDP, and prolonged APTT and PT | replacement treatment and antifibrinolytic treatment: cryoprecipitate, fibrinogen concentrate | (9)       |

Toxicities related to CAR-T cell therapy) Given that cytokine storm plays an essential role in CRS-related coagulopathy, the early and effective management of CRS might be helpful to reduce the incidence of coagulopathy. Without timely and effective intervention, a part of patients with coagulopathy may further develop disseminated intravascular coagulation (DIC), accompanied by the poor prognosis (9, 156, 158).

The mechanisms of CRS-related coagulopathy remain unclear. The activated platelets, monocytes, and endothelial cells as well as the CD40/CD40L interactions between them may collectively contribute to CRS-related coagulopathy. The CD40L expressed on activated CAR-T cells induces platelet activation in a CD40-independent manner in blood circulation (159). The activated platelets are prone to the formation of monocyte-platelet aggregates (MPAs) and are highly express CD40L, which could induce the expression of tissue factor (TF) in monocytes and endothelial cells through the direct interaction with CD40 (159–162). TF could activate the extrinsic coagulation cascade, and monocytes are the major sources of TF. Besides the CD40/CD40L interactions, there are also a variety of inducers that could stimulate monocytes to upregulate the expression of TF, such as C-reactive protein (CRP), IL-1β and TNF-α (163–165). In addition, the CD40/CD40L interactions between them promote the excessive production of cytokines as well, such as IL-1β, TNF-α, and IL-6. High levels of cytokines further mediate endothelial injury and result in the release of TF, the procoagulant particles Weibel-Palade bodies (WPBs), and von Willebrand factor (VWF) as well as the exposure of the collagen fibers. The exposed collagen fibers trigger intrinsic coagulation pathway. In addition, cytokines IL-6, TNF-α, and IFN-γ can directly inhibit the production and activity of ADAMTS13, which contributes to the elevated levels VWF in blood and promote platelet adhesion and aggregation (166, 167). Moreover, serious liver damage induced by CAR-T cell therapy influences the production of coagulation factors, and some patients with hematological malignancies had been in a hypercoagulable state prior to CAR-T cell therapy (168) (Figure 4).

RESISTANCE TO CAR-T CELL THERAPY AND POTENTIAL EFFECTIVE STRATEGIES

However, with the widespread application of CAR-T cell therapy in R/R B-cell malignancies, a considerable proportion of patients relapse after CAR-T cell therapy. There are multiple factors which contribute to relapse after CAR-T cell therapy, including antigen escape, the limited CAR-T cell persistence, and immunosuppressive tumor microenvironment. There are some therapeutic strategies to overcoming the resistance to CAR-T cell therapy, including the application of bispecific or armed CAR-T cells, optimizing the CAR structure, combining CAR-T cell therapy with other approaches, such as small-molecule drugs, localized radiotherapy, and oncolytic viruses.

Overcoming Antigen Escape

Although CAR-T cell therapy has made impressive achievements in R/R B cell malignancies, a majority of patients still relapse (143). One of the primary mechanisms of relapse after CAR-T cell therapy is antigen loss (169, 170). The antigen mutations under therapeutic pressure of CAR-T cell therapy are the most common mechanisms of antigen loss, including splice variants, lineage switching, and biallelic mutations (171–173). In addition to antigen mutations, the lower antigen density on the surface of induced by the endocytosis of CAR-T cells could promote tumor immune escape as well (174). Last but not least, a study has reported that the anti-CD19 CAR was incidentally transferred into a leukemic B cell during CAR-T cell manufacturing and then bound to the CD19 epitope on leukemic blasts, so “epitope-
masking” prevented leukemic blasts from being recognized by anti-CD19 CAR-T cells (175).

Targeting distinct antigens is one of the most effective approaches to overcome antigen-negative relapse. The dual-targeting CAR-T cells which could recognize two distinct target antigens have been demonstrated to reduce the risk of antigen-negative relapse, such as the bispecific CAR-T cells in B cell lymphoma/leukemia and the APRIL-based CAR-T cells targeting both BCMA and TACI in MM (86, 176–180). The multi-targeted CAR-T cells have also been explored. It has been demonstrated that the tri-specific CD19-CD20-CD22-targeting CAR-T cells could rapidly eliminate B cell lymphoma in a preclinical study (181), and BAFF ligand-based CAR-T cells simultaneously target three receptors, including BAFF-R, BCMA, and TACI (182). In addition to simultaneously targeting different antigens, increasing immunogenicity of target cells might be a feasible strategy. For example, small molecule γ-secretase inhibitors could reduce the shedding of BCMA and promote the recognition of MM cells by CAR-T cells (183).

The γδ T cells (γδ T) are a small population of peripheral blood cytotoxic T cells, which express both T cell receptors (TCRs) and natural killer receptors (NKRs), and involved in anti-tumor immunity. In particular, NKRs expressed on γδ T cells play a major role in tumor cell recognition in hematological malignancies (184–186). Thus, besides antigen recognition mediated by the scFvs, γδ CAR-T cells could also recognize antigen-negative leukemia cells via NKRs in an MHC-independent manner (187). Moreover, γδ T cells did not induce graft-versus-host disease (GVHD) in allogeneic and HLA-haploidentical hematopoietic stem cell transplantation, which indicates that γδ T cells don’t trigger alloreactivity (188, 189). Thus, they are more suitable for the development of universal CAR-T cells.

**Regulating the Persistence of CAR-T Cells**

The short-term persistence of CAR-T cells limits their anti-tumor efficacy and may result in antigen-positive relapse. There are multiple strategies to improve the persistence of CAR-T cells, such as optimizing CAR-T cell construct, utilizing memory T cells, and rationally designing the ratio of CD4 to CD8 CAR-T cells (190). To date, CD28 and 4-1BB are the most common co-stimulatory molecules in CAR-T cell products. However, it has been demonstrated that 4-1BB co-stimulation could ameliorate CAR-T cell exhaustion compared with CD28 co-stimulation (191, 192). Remarkably, combining CD28 and 4-1BB could simultaneously augment the anti-tumor effects and increase the persistence of CAR-T cells (193–196). In addition, the CAR-T cell structure can be optimized by the fully humanized CARs. The humanized CAR-T cells could avoid the rejection by the host immune system, and they were still effective in R/R patients who have failed in prior murine CAR-T cell therapy (68, 197). CD4+ T cells exhibit developmental plasticity and can directly kill tumor cells (198), but they eliminate tumor cells at the slower rate and release the lower levels of Granzyme B than CD8+ T cells. Thus, CD4+ CAR-T cells exhibit a superior persistence (199–202), and the ratio of CD4/CD8 CAR-T cells may influence their therapeutic efficacy. Currently, CD4/CD8 CAR-T cells at a 1:1 ratio have been demonstrated to exert excellent anti-tumor effects (200). CAR-T cells have been considered as “living drugs”, but they lack the precise regulation. Given that the excessive expansion of
CAR-T cells could lead to the life-threatening CRS, so it is necessary to regulate the expansion and persistence of CAR-T cells to mitigate unexpected or severe toxicities through the addition of the safety switches. The well-known inducible caspase 9 (iCasp9) suicide gene and the small molecule control systems have been explored (203, 204). In small molecule control systems, the FDA-approved small molecule drugs act as the key switches to specifically regulate antigen recognition or deplete CAR-T cells, such as lenalidomide, methotrexate, alemtuzumab, rituximab, and cetuximab (31, 63, 205–208), as well as orthogonal IL-2 (205, 206). The above-mentioned monoclonal antibodies mediate the depletion of CAR-T cells through antibody-dependent cell-mediated cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) (63, 209). Nevertheless, the depletion of CAR-T cells is slow in this strategy, which may be not suitable for patients with severe toxicities.

Improving Anti-Tumor Efficacy of CAR-T Cell Therapy Through Combinatorial Strategies

The low activity of CAR-T cells could also limit the efficacy of CAR-T cell therapy. Multiple immune-stimulatory molecules, including certain cytokines or co-stimulatory molecules, have been demonstrated to play an important role in regulating the development and function of T cells, such as IL-7, IL-12, IL-15, IL-18, IL-21, and CD40L (109, 210–214). They could promote the robust expansion of the CAR-T cells and increase memory-phenotype CAR-T cells as well as improving their persistence (215–218). In addition to adding these exogenous cytokines, the genetic modifications to constitutively express these immune-stimulatory molecules or their receptors could also improve the function of CAR-T cells (10, 213, 219, 220). These fourth-generation CAR-T cells have showed the improved anti-tumor activities by stimulating the activation of themselves or endogenous immune cells in an autocrine or paracrine manner (11, 220–222).

To improve the efficacy of CAR-T cell therapy, combining CAR-T cell therapy with small-molecule drugs appears to be promising and may produce synergistic effects. The selective inhibitors of nuclear export selinexor, lenalidomide and carfilzomib have been approved for the treatment of MM (223, 224). Intriguingly, combining them with CAR-T cells also achieved encouraging outcomes, with the improved cytotoxic activity and cytokine production of CAR-T cells (225, 226). In particular, the recent clinical studies showed that the R/R MM patients resistant to anti-BCMA CAR-T cell therapy could also benefit from selinexor-based regimens and carfilzomib-based regimens (227, 228), and a study reported that anti-BCMA CAR-T cell therapy combined with lenalidomide was effective in the R/R MM patients who had previously relapsed after anti-BCMA CAR-T cell therapy (229). Ibrutinib, a well-known Bruton’s tyrosine kinase inhibitor, has been approved for the treatment of CLL and MCL. Importantly, Ibrutinib not only improved CAR T cell anti-tumor efficacy in both preclinical and clinical studies, but also reduced the risk of severe CRS (230–233). In addition, it has been demonstrated that demethylating agents azacitidine and decitabine could enhance cytotoxic effect of CAR-T cells as well (234–236). Besides, CAR-T cell therapy in combination with inhibitors of antiapoptotic proteins could overcome the resistance induced by antiapoptotic proteins (237). However, CAR-T cell therapy combined with small-molecule drugs is still in its infancy, and numerous combinational strategies are being explored.

Additionally, the localized radiotherapy could serve as a well-tolerated and effective bridging strategy between the leukapheresis and CAR-T cell infusion for lymphoma or MM patients with bulky disease (238–240). On the one hand, this combinational therapy could prevent disease progression and reduce tumor burden; On the other hand, it may sensitize the CAR-T cells through the abscopal effect, which may be associated with the upregulation of intratumoral chemokines and cytokines, the release of neo-antigens, and the activation of endogenous immune cells (241–245). Nonetheless, the optimal irradiation dose and fractionation remain to be identified.

Overcoming Immunosuppressive Microenvironment

While directly targeting tumor cells is important, it is also critical to overcome the immunosuppressive tumor microenvironment. Although tumor microenvironment is believed to play a relatively minor role in drug resistance in hematological malignancies, MM, leukemia, and lymphoma microenvironment also contains tumor supportive components, such as stromal cells, myeloid-derived suppressor cells, regulatory T-cells, tumor-associated macrophages, and tumor-associated neutrophils (246–250), which interact closely with malignant cells and promote their survival as well as immune escape (250–253). In addition, these immunosuppressive components impair the cytotoxic effects of CAR-T cells and result in CAR-T cell exhaustion (248, 249). Therefore, it is also necessary to overcome the immunosuppressive microenvironment in hematological malignancies. In addition to armored CAR-T cells, CAR-T cell therapy in combination with checkpoint blockades or oncolytic viruses also appears to be an appealing strategy.

The PD-1/PD-L1 pathway plays a major role in T cell exhaustion and represents a major mechanism of tumor immune escape. Thus, blockage of PD-1/PD-L1 interaction could promote the immune system to fight against cancer cells, and PD-1 blockade has achieved tremendous success in diverse tumor types in recent years, especially in lymphoma (254, 255). PD-1 blockade is usually administrated in combination with conventional chemotherapy or other immunotherapies. Currently, multiple studies have explored the combination therapy with CAR-T cells and PD-1 blockade (Table 3 combinational strategies with CAR-T cell therapy). In a clinical trial enrolled 11 NHL patients, 45.5% of patients achieved CRs after this combinational therapy, and the toxicities were well-tolerable (256, 257). The mechanisms may be mainly attributed to the decreased CAR-T cell exhaustion (258–260). In addition, the CAR-T cells which could secrete the PD-1 blocking scFv have been developed. The preclinical study demonstrated that the efficacy of such CAR-T cells was equally effective or superior to the combinational therapy of CAR-T cells...
and PD-1 inhibitor (261). TIM-3 is another inhibitory immune checkpoint, and the combination of TIM-3 blockade with CAR-T cells exerts synergistic anti-tumor activity as well (262).

The combination of CAR-T cell therapy and oncolytic viruses is an innovative strategy to overcome immunosuppressive microenvironment. The virus-infected tumor cells which carry pathogen-associated molecular patterns (PAMPs) could recruit host immune cells and thereby promote the recognition of TAAs by the host immune system and the oncolytic viruses also can be genetically modified with immune-stimulatory molecules to enhance the anti-tumor activity of CAR-T cells (263, 264). Besides, oncolytic viruses directly lyse tumor cells and result in the release of TAAs and damage-associated molecular patterns (DAMPs), which could increase tumor immunogenicity and activate APCs through pattern recognition receptors (PRRs), eventually activating tumor-specific T cells (265–267).

In addition, the armored CAR-T cells which express the immune-regulatory molecules, such as IL-15, IL-18, CD40L as well as TGF-β dominant-negative receptor II, are able to remodel the tumor microenvironment (211, 219, 220, 268). Oncometabolites in the tumor microenvironment could inhibit the metabolism and function of CAR-T cells, so suppressing the accumulation oncometabolites is a potential therapeutic option. Kynurenine (Kyn) is an oncometabolite which exists in various hematopoietic malignancies, such as lymphoma and leukemia, and the enzyme kynurenine catalyzes the degradation of Kyn. Thus, the anti-CD19 CAR-T cells were genetically modified with the enzyme kynurenine gene, and they exhibited the improved anti-tumor activity against Nalm6-GL cells in the immunosuppressive tumor microenvironment with high Kyn (269). Interestingly, some target antigens are co-expressed on immunosuppressive cells in tumor microenvironment, so targeting these antigens can simultaneously eliminate malignant cells and immunosuppressive cells. For example, anti-CD123 CAR-T cells target both malignant cells and TAMs in HL (270).

### CONCLUSIONS

There are many challenges and opportunities presented by CAR-T cell therapy. With the identification of novel therapeutic targets and the optimization of CAR constructs, CAR-T cell therapy will have broader clinical applications, beyond hematological malignancies. However, with the rapid commercialization of CAR-T cell therapy, it poses a significant challenge for the management of CAR-T cell therapy, such as the toxicities associated with CAR-T therapy and relapse after CAR T-cell therapy. Therefore, exploring their underlying mechanisms and overcoming these limitations will help R/R patients gain more benefits from this promising. Currently, multiple combinatorial approaches with CAR-T cell therapy are being explored and seem to be promising immunotherapy. In addition, UCAR-T cells and CAR-NK cells also show great potential in cancer treatment due to their low manufacturing costs and off-the-shelf availability.

### AUTHOR CONTRIBUTIONS

YX, XZ, and LZ designed the manuscript. XZ, HZ, and SC drafted the manuscript and created the figures. XZ and YX revised the manuscript. All authors read and approved the final manuscript.

### FUNDING

This work was supported by the National Natural Science Foundation of China (Grant No. 81973583 and 81873426), and Guangdong Basic and Applied Basic Research Foundation (2021A1515011575).

### REFERENCES

1. Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in Children and Young Adults With B-Cell Lymphoblastic Leukemia. *N Engl J Med* (2018) 378(5):439–48. doi: 10.1056/NEJMoai1709866
2. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med* (2019) 380:45–56. doi: 10.1056/NEJMoai1804980
3. Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, et al. Tisagenlecleucel in Adult Relapsed or Refractory Follicular Lymphoma: The Phase 2 ELARA Trial. *Nat Med* (2021) 27(2):325–32. doi: 10.1038/s41591-021-01622-0
4. Locke FL, Ghobadi A, Jacobson CA, Miklos DB, Lekakis LJ, Oluwole OO, et al. Long-Term Safety and Activity of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1): A Single-Arm, Multicentre, Phase 1-2 Trial. *Lancet Oncol* (2019) 20(1):31–42. doi: 10.1016/S1470-2045(18)30864-7

---

**TABLE 3 | Combinatorial strategies with CAR-T cell therapy reported in clinical studies.**

| Combinatorial approach          | Disease               | Target | Reference |
|--------------------------------|-----------------------|--------|-----------|
| PD-1 blockade                   | R/R NHL              | CD19   | (256, 257) |
| Ibrutinib                       | R/R CLL, MCL, FL     | CD19   | (230, 231, 233) |
| Radiotherapy                    | R/R NHL              | CD19   | (238–241) |
| Decitabine                      | R/R NHL              | CD19   | (236)     |
| Lenalidomide                    | R/R MM               | BCMA   | (229)     |
| Selinexor-based regimens        | R/R MM               | BCMA   | (228)     |
| Carfilzomib-based regimens      | R/R MM               | BCMA   | (227)     |

---

---

---
5. Wang M, Munoz J, Gey A, Locke FL, Jacobson CA, Hill BT, et al. KTE-X19 CAR-T Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. *N Engl J Med* (2020) 382(14):1331–42. doi: 10.1056/NEJMoai1914347

6. Abrahamson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnamson J, et al. Lisocabtagene Maraleucel for Patients With Relapsed or Refractory Large B-Cell Lymphomas (TRANSSEND NHL 001): A Multicentre Seamless Design Study. *Lancet* (2020) 396(10254):839–52. doi: 10.1016/S0140-6736(20)33660-0

7. Berdeja JG, Madduri D, Usmani SZ, Jakubowiak A, Agha M, Cohen AD, et al. Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Patients With Relapsed or Refractory Multiple Myeloma (CAR-TIME 1): A Phase 1b/2 Open-Label Study. *Lancet* (2021) 398(10297):314–24. doi: 10.1016/S0140-6736(21)09933-8

8. Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lorial S, et al. Idecabtagene Vicelucel in Relapsed and Refractory Multiple Myeloma. *N Engl J Med* (2021) 384(8):705–16. doi: 10.1056/NEJMoa204850

9. Jiang H, Liu L, Guo T, Wu Y, Ai L, Deng J, et al. Improving the Safety of CAR-T Cell Therapy by Controlling CRS-Related Coagulopathy. *Ann Hematol* (2019) 98(7):1721–32. doi: 10.1007/s00277-019-03685-z

10. Lanitis E, Rota G, Kostis P, Ronet C, Spill A, Seijo B, et al. Optimized Gene Engineering of Murine CAR-T Cells Reveals the Beneficial Effects of IL-15 Coexpression. *J Exp Med* (2021) 218(2):e20192203. doi: 10.1084/jem.20192203

11. Duan D, Wang K, Wei C, Feng D, Liu Y, He Q, et al. The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma. *Front Immunol* (2021) 12:609421. doi: 10.3892/immunol.2021.609421

12. Yang J, Jiang P, Zhang X, Li J, Wu Y, Xu L, et al. Successful 24-Hours Manufacture of Anti-CD19/CD22 Dual Chimeric Antigen Receptor (CAR) T Cell Therapy for B-Cell Acute Lymphoblastic Leukemia (B-ALL). *Blood* (2020) 136(Supplement 1):2–3. doi: 10.1182/blood-2020-136866

13. Jiang H, Dong B, Gao L, Liu L, Ge J, He A, et al. Clinical Results of a Multicenter Study of the First-in-Human Dual BCMA and CD19 Targeted Novel Platform Fast CAR-T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma. *Blood* (2020) 136(Supplement 1):25–6. doi: 10.1182/blood-2020-136866

14. Hu Y, Wang J, Wei G, Yu J, Luo Y, Shi J, et al. A Retrospective Comparison of Autologous and Allogeneic Chimeric Antigen Receptor T Cell Therapy Targeting CD19 in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. *Bone Marrow Transplant* (2019) 54(8):1208–17. doi: 10.1038/s41409-018-0403-z

15. Liu E, Marin D, Baranjeer P, Macapinlac HA, Thompson P, Basar R, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. *N Engl J Med* (2020) 382(6):545–53. doi: 10.1056/NEJMoai1910607

16. Jacobson CA, Chavez JC, Sahgal AR, William BM, Munoz J, Salles G, et al. Axicabtagene Ciloleucel in Relapsed or Refractory Indolent non-Hodgkin Lymphoma (ZUMA-5): A Single-Arm, Multicentre, Phase 2 Trial. *Lancet Oncol* (2022) 23(1):91–103. doi: 10.1016/S1470-2045(21)00591-X

17. Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, et al. Axicabtagene Ciloleucel in Relapsed or Refractory Indolent non-Hodgkin Lymphoma (ZUMA-5): A Single-Arm, Multicentre, Phase 2 Trial. *Lancet Oncol* (2022) 23(1):91–103. doi: 10.1016/S1470-2045(21)00591-X

18. Zelenetz AD, Gordon LI, Chang JE, Christian B, Abramson JS, Advani RH, et al. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021. *J Natl Compr Canc Netw* (2021) 19(11):1218–30. doi: 10.6004/jnccn.2021.00354

19. Pan J, Yang JF, Deng BP, Zhao XJ, Zhang X, Lin YH, et al. High Efficacy and Safety of Low Dose CD19 DIRECT CAR-T Cell Therapy in 51 Relapsing or Relapsed B Acute Lymphoblastic Leukemia Patients. *Leukemia* (2017) 31:2587–93. doi: 10.1038/leu.2017.145

20. Wang Y, Zhang WY, Han QW, Liu Y, Dai HR, Guo YL, et al. Effective Response and Delayed Toxicities of Refractory Advanced Diffuse Large B-Cell Lymphoma Treated by CD20-Directed Chimeric Antigen Receptor-Modified T Cells. *Clin Immunol* (2014) 155(2):160–75. doi: 10.1016/j.clim.2014.08.002

21. Wang Y, Liu Y, Wang Y, Wang CM, Yang QM, Zhu HL, et al. Long-Term Safety and Efficacy of CART-20 Cells in Patients With Refractory or Relapsed B-Cell non-Hodgkin Lymphoma: 5-Years Follow-Up Results of the Phase I and IIa Trials. *Signal Transduct Target Ther* (2017) 2:17054. doi: 10.1038/s41388-2017-054
Zhang et al. CAR-T Therapy in Hematological Malignancies

Phase 3 Trial. *Lancet* (2019) 393:229–40. doi: 10.1016/S0140-6736(18)32984-2

Farooq MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, et al. Five-Year Outcomes for Frontline Brentuximab Vedotin With CHP for CD30-Expressing Peripheral T-Cell Lymphomas. *Blood* (2018) 131(19):2120–4. doi: 10.1182/blood-2017-12-821009

Guercio M, Orlando D, Di Cecca S, Sinibaldi M, Boffa I, Caruso S, et al. CD28.OX40 Co-Stimulatory Combination is Associated With Long In Vivo Persistence and High Activity of CAR.CD30 T-Cells. *Haematologica* (2021) 106(4):987–99. doi: 10.3324/haematol.2019.231183

Wu Y, Chen D, Lu Y, Dong SC, Ma R, Tang WY, et al. A New Immunotherapy Strategy Targeted CD30 in Peripheral T-Cell Lymphomas: CAR-Modified T-Cell Therapy Based on CD30 mAb. *Cancer Gene Ther* (2022) 29(2):167–77. doi: 10.1038/s41417-021-02295-8

Wang CM, Wu ZQ, Wang Y, Guo YL, Dai HR, Wang XH, et al. Autologous T Cells Expressing CD30 Chimeric Antigen Receptors for Relapsed or Refractory Hodgkin Lymphoma: An Open-Label Phase I Trial. *Clin Cancer Res* (2017) 23(5):1156–66. doi: 10.1158/1078-0432.CCR-16-1365

Ramos CA, Grover NS, Beaven AW, Lulla PD, Wu MF, Ivanova A, et al. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. *J Oncol* (2020) 38(32):7934–804. doi: 10.1200/ JCO.20.01342

Ramos CA, Ballard B, Zhang H, Dakhova O, Gee AP, Mei Z, et al. Targeting CD30 With Cusatuzumab Eliminates Acute Myeloid Leukemia Stem Cells in Patients Treated With Hypomethylating Agents. *Nat Med* (2020) 26(9):1459–67. doi: 10.1038/s41591-020-0910-8

John S, Chen H, Deng M, Gui X, Wu G, Chen W, et al. A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML. *Mol Ther* (2018) 26(10):2487–95. doi: 10.1016/j.ymthe.2018.08.001

Jetani H, Navarro-Bailon A, Maucher M, Frenz S, Breuggen C, Yeguas A, et al. Sigle-6 is a Novel Target for CAR-T Cell Therapy in Acute Myeloid Leukemia. *Blood* (2021) 138(19):1830–42. doi: 10.1182/blood.2020009192

Xie G, Ivica NA, Jia B, Li Y, Dong H, Liang Y, et al. CAR-T Cells Targeting a Nucleophosmin Neeoptosepote Exhibit Potent Specific Activity in Mouse Models of Acute Myeloid Leukemia. *Nat BioMed Eng* (2021) 5(9):399–413. doi: 10.1038/s41551-020-0625-5

Sommer C, Cheng HY, Nguyen D, Dettling D, Yeung YA, Sutton J, et al. Allogeneic FLT3 CAR T Cells With an Off-Switch Exhibit Potent Activity Against AML and Can Be Depleted to Expedite Bone Marrow Recovery. *Mol Ther* (2020) 28(10):2237–51. doi: 10.1016/j.ymthe.2020.06.022

Jetani H, Garcia-Cadenas I, Nerreret T, Thomas S, Rydzek J, Meijide JB, et al. CAR T-Cells Targeting FLT3 Have Potent Activity Against FLT3-ITD AML and Act Synergistically With the FLT3-Inhibitor Crenolanib. *Leukemia* (2018) 32(5):1168–79. doi: 10.1038/s41375-018-0009-0

Kikushige Y, Yoshimoto G, Miyamoto T, Iino T, Mori Y, Iwasaki H, et al. Human FLT3 is Expressed at the Hematopoietic Stem Cell and the Granulocyte/Macrophage Progenitor Stages to Maintain Cell Survival. *Immunol* (2008) 180:735–46. doi: 10.4099/immunol.180.117358

Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group Updated Criteria for the Diagnosis of Multiple Myeloma. *Lancet Oncol* (2014) 15(12):e538–48. doi: 10.1016/S1470-2045(14)70442-5

Shah N, Chari A, Scott E, Mezzi K, Usmani SZ. B-Cell Maturation Antigen (BCMA) in Multiple Myeloma: Rationale for Targeting and Current Therapeutic Approaches. *Leukemia* (2020) 34(4):985–1005. doi: 10.1038/s41375-020-0734-z

Wang D, Wang J, Hu G, Wang W, Xiao Y, Cai H, et al. A Phase 1 Study of a Novel Fully Human BCMA-Targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma. *Blood* (2021) 137(21):2890–901. doi: 10.1182/blood.2020008936

Li L, Cao W, Que Y, Wang Q, Xiao Y, Gu C, et al. A Phase I Study of Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Leukemia. *Clin Transl Med* (2021) 11(3):e346. doi: 10.1002/ ctm2.346

Sharma P, Kanapuru B, George B, Lin X, Zun Bryan WW, et al. FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma. *Clin Cancer Res* (2022) 28(9): 1759–64. doi: 10.1158/1078-0432.CCR-21-3803

Deng H, Liu M, Yuan T, Zhang H, Cui R, Li J, et al. Efficacy of Humanized Anti-BCMA CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With and Without Extramedullary Disease. *Front Immunol* (2021) 12:720571. doi: 10.3389/fimmu.2021.720571

Que Y, Xu M, Xu Y, Almeida VDF, Zhu L, Wang Z, et al. Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials. *Front Immunol* (2021) 12:755866. doi: 10.3389/fimmu.2021.755866

Oriol A, Abril L, Torrent A, Ibarra G, Ribera JM. The Role of Idecabtagene Vicleucel in Patients With Heavily Pretreated Refractory Multiple Myeloma.
Patients After Chimeric Antigen Receptor T Cell Therapy. J Interferon Cytokine Res (2021) 41(12):469–76. doi: 10.1089/jir.2021.0057

Norelli M, Camus B, Barboud G, Falzone L, Pau B, Genn A, Genua M, et al. Monocytone-Derived IL-1 and IL-6 are Differentially Required for Cytokine-Release Syndrome and Neurotoxicity Due to CAR T Cells. Nat Med (2018) 24(6):739–48. doi: 10.1038/s41591-018-0036-4

Giovardis T, van der Sten SJC, Eyyuem J, Hamieh M, Piersigili A, Sadelain M. CAR T Cell-Induced Cytokine Release Syndrome is Mediated by Macrophages and Abated by IL-1 Blockade. Nat Med (2018) 24(6):731–8. doi: 10.1038/s41591-018-0041-7

Wehrli M, Gallagher K, Chen YB, Leic MB, McAfee SL, El-Jawahri AR, et al. Single-Center Experience Using Anakina for Steroid-Refractory Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS). J Immunother Cancer (2022) 10(1):003847. doi: 10.1136/jitc-2021-003847

Mehta P, Cron RQ, Hartwell J, Manson J, Tattersall RS. Silencing the Cytokine Storm: The Use of Intrastravenous Anakina in Haemophagocytic Lymphohistiocytosis or Macrophage Activation Syndrome. Lancet Rheumatol (2020) 2(6):e358–67. doi: 10.1016/S2352-3026(20)30096-5

Strati P, Ahmed S, Kebriaei P, Nastouli LJ, Claussen CM, Watson G, et al. Clinical Effectiveness of Anakina to Mitigate CAR T-Cell Therapy-Associated Toxicity in Large B-Cell Lymphoma. Blood Adv (2020) 4(13):3123–7. doi: 10.1182/bloodadvances.2020002328

Sterner RM, Sakemura R, Cox MJ, Yang N, Khadka RH, Forsman CL, et al. GM-CSF Inhibition Reduces Cytokine Release Syndrome and Neuroinflammation But Enhances CAR-T Cell Function in Xenografts. Blood (2019) 133(7):697–709. doi: 10.1182/blood-2018-10-881722

Sachdeva M, Duchateau P, Depil S, Poirot L, Valton J. Granulocyte-Macrophage Colony-Stimulating Factor Inactivation in CAR T-Cells Prevents Monocytone-Dependent Release of Key Cytokine Release Syndrome Mediators. J Biol Chem (2019) 294(1):5430–7. doi: 10.1074/jbc.A119.007558

Liu Y, Fang Y, Chen X, Wang Z, Liang X, Zhang T, et al. Gasdermin E-Mediated Target Cell Pyroptosis by CAR T Cells Triggers Cytokine Release Syndrome. Sci Immunol (2020) 5(43):eaa7969. doi: 10.1126/sciimmunol.aax7969

Gong T, Liu L, Jiang W, Zhou R. DAMP-Sensing Receptors in Sterile Inflammation and Infectious Diseases. Nat Rev Immunol (2020) 20(2):95–112. doi: 10.1038/s41577-019-0215-7

Broz P, Pelegrin P, Shao F. The Gasdermins, a Protein Family Executing Cell Death and Inflammation. Nat Rev Immunol (2020) 20(3):143–57. doi: 10.1038/s41577-019-0228-2

Deng T, Tang C, Zhang G, Wan X. DAMPs Released by Pyroptotic Cells as Major Contributors and Therapeutic Targets for CAR-T-Related Toxicities. Cell Death Dis (2021) 12(1):129. doi: 10.1038/s41431-021-00342-x

Singh N, Hofmann TJ, Gehrig N, Zucchi LL, Grupp SA, Teachey DT. Monocyte Lineage-Dependent IL-6 Does Not Affect Chimeric Antigen Receptor T-Cell Function. Cytotherapy (2017) 19(7):867–80. doi: 10.1016/j.jcyt.2017.04.001

Hao Z, Li R, Meng L, Han Z, Hong Z. Macrophage, the Potential Key Mediator in CAR-T-Related CRS. Exp Hematol Oncol (2020) 9:15. doi: 10.1186/s41064-020-00171-5

Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular Mechanism and Function of CD40-CD40L Engagement in the Immune System. Immunol Rev (2009) 229(1):152–72. doi: 10.1111/j.1600-065X.2009.00782.x

Qi C, Tian S, Wang J, Ma H, Qian K, Zhang X. Co-Expression of CD40/CD40L on XGI Multiple Myeloma Cells Promotes IL-6 Autocrine Function. Cancer Invest (2015) 33(11):1283–92. doi: 10.1080/07357907.2014.988340

Pellat-Deceunynck C, Amiot M, Robillard N, Wijdenes J, Bataille R. CD11a/CD18 and CD102 Interactions Mediate Human Myeloma Cell Growth Arrest Induced by CD40 Stimulation. Cancer Res (1996) 56:1909–16.

Toeb G, Tai YT, Urashima M, Shirahama S, Matsuzaki M, Chauhan D, et al. CD40 Activation Mediates P53-Dependent Cell Cycle Regulation in Human Multiple Myeloma Cell Lines. Blood (2000) 95(3):1039–46. doi: 10.1182/blood.V95.3.1039.003032_1039_1046
180. Dai H, Wu Z, Jia H, Tong C, Guo Y, Ti D, et al. Bispecific CAR-T Cells Targeting Both CD19 and CD22 for Therapy of Adults With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia. J Hematol Oncol (2020) 13(1):30. doi: 10.1186/s13045-020-00856-8

181. Schneider D, Xiong Y, Wu D, Hu P, Alanbazi L, Steinble M, et al. Trispecific CD19-CD20-CD22-Targeting duoCAR-T Cells Eliminate Antigen-Heterogeneous B Cell Tumors in Preclinical Models. Sci Transl Med (2021) 13(586):eabc6401. doi: 10.1126/scitranslmed.abc6401

182. Wong DP, Roy NK, Zhang K, Anukanth A, Asthana A, Shirkey-Son NJ, et al. 4-1BB and

194. Roselli E, Boucher JC, Li G, Kotani H, Spitler K, Reid K, et al. In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes. Mol Ther (2020) 28(8):1783–94. doi: 10.1016/j.ymthe.2020.05.005

192. Li G, Boucher JC, Kotani H, Park K, Zhang Y, Shrestha B, et al. 4-1BB Against Leukemia. Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia. Front Immunol (2020) 11:1347. doi: 10.3389/fimmu.2020.01347

194. Agarwal S, Hanauer JDS, Frank AM, Riechert V, Thalheimer FB, Buchholz CJ. In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes. Mol Ther (2020) 28(8):1783–94. doi: 10.1016/j.ymthe.2020.05.005

196. Romeo M, Li, Hsiao, P, Wadhwa, S, Menezes, S, et al. A BAFF Ligand-Based CAR-T Cell Targeting Three Receptors and Multiple B Cell Cancers. Nat Commun (2022) 13(1):217. doi: 10.1038/s41467-021-27853-w

198. Wang Q, Hresko ME, Picton LK, Su L, Hollander MJ, Nunez-Cruz S, et al. An Orthogonal IL-2 and IL-2rβ System Drives Persistence and Activation of CAR T Cells and Clearance of Bulk Lymphoma. Sci Transl Med (2021) 13(625):eabg6295. doi: 10.1126/scitranslmed.abg6295

200. Turtle CJ, Hanaei LA, Berger C, Gooley TA, Cherian S, Hudecek M, et al. CD19 CAR-T Cells of Defined CD4+CD8+ Composition in Adult B Cell ALL Patients. J Clin Invest 2016; 126(6):2123–38. doi: 10.1172/JCI83509

202. Melenhorst JJ, Chen GM, Wang M, Porter DL, Chen C, Collins MA, et al. Decade-Long Leukaemia Remissions With Persistence of CD4+ CAR T Cells. Nature (2022) 602(2879):503–9. doi: 10.1038/s41586-021-04390-6

206. Zhang Q, Hresko ME, Picton LK, Su L, Hollander MJ, Nunez-Cruz S, et al. An Orthogonal IL-2 and IL-2rβ System Enhances CAR T Cell Function. JCI Insight (2017) 2(3):580. doi: 10.1172/jci.insight.90

210. Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provias E, et al. IL-7 and IL-15 Instruct the Generation of Human Memory Stem T Cells From Naïve Precursors. Blood (2013) 121(4):573–84. doi: 10.1182/blood-2012-05-431718

212. Shum T, Omer B, Tashiro H, Kruse RL, Wagner DL, Parikh K, et al. Reversible ON- and OFF-Switch Chimeric Antigen Receptors Controlled by Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells. Mol Ther (2017) 25(3):580–92. doi: 10.1038/ymte.2017.01011

214. Park S, Pascua E, Lindquist KC, Deng X, Mak YSL, et al. Direct Control of CAR T Cells Through Small Molecule-Regulated Antibodies. Nature (2021) 121(7):170. doi: 10.1038/s41467-020-20671-6

216. Paszkiewicz PJ, Frâlë SP, Srivastava S, Sommermeyer H, Hudecek M, Drexler I, et al. Targeted Antibody-Mediated Depletion of Murine CD19 CAR T Cells Permanently Reverses B Cell Aplasia. J Clin Invest (2016) 126(11):4362–72. doi: 10.1172/JCI84813

218. Arai, O, Arai, H, Trapani, A, et al. Interleukin-10-STAT3 Pathway is Critical for Functional Maturation of CD4+CD25+ TReg Cells. Mol Ther (2016) 24(6):1205–15. doi: 10.1038/mt.2016.131

220. Cui W, Liu Y, Weinstein JS, Craft J, Kaech SM. An Interleukin-21-Interleukin-10-STAT3 Pathway is Critical for Functional Maturation of Memory CD8+ T Cells. Immunity (2011) 35(5):792–805. doi: 10.1016/j.immuni.2011.09.017

222. Battram AM, Bachiller M, Lopez V, Fernandez de la Riva C, Urbano-Ispizua A, Martin-Antonio B. IL-15 Enhances the Persistence and Function of BCMA-Targeting CAR-T Cells Compared to IL-2 or IL-15/IL-7 by Limiting CAR-T Cell Dysfunction and Differentiation. Cancers (Basel) (2021) 13(14):3534. doi: 10.3390/cancers13143534...
251. Kline J, Godfrey J, Ansell SM. The Immune Landscape and Response to Immune Checkpoint Blockade Therapy in Lymphoma. *Blood* (2020) 135 (8):523–33. doi: 10.1182/blood.2019000847

252. Crespo J, Sun H, Welling TH, Tian Z, Zhou W, T Cell Anergy, Exhaustion, Senescence, and Stemness in the Tumor Microenvironment. *Curr Opin Immunol* (2013) 25:214–21. doi: 10.1016/j.coi.2012.12.003

253. Dhakal B, Hari PN, Usmani SZ, Hamadani M. Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: Promise and Challenges. *Bone Marrow Transplant* (2021) 56(1):9–19. doi: 10.1038/s41409-020-01023-w

254. Hatic H, Sampat D, Goyal G. Immune Checkpoint Inhibitors in Lymphoma: Challenges and Opportunities. *Ann Transl Med* (2021) 9(12):1037. doi: 10.4103/atm.atm_1586_20

255. Song MK, Park BB, Uhm J. Understanding Immune Evasion and Therapeutic Targeting Associated With PD-1/PD-L1 Pathway in Diffuse Large B-Cell Lymphoma. *Int J Mol Sci* (2019) 20(6):1326. doi: 10.3390/ijms20061326

256. Cao Y, Lu W, Sun R, Jin X, Cheng L, He X, et al. Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab are Safe and Effective Against Relapsed/Refractory B-Cell non-Hodgkin Lymphoma. *Front Oncol* (2019) 9:767. doi: 10.3389/fonc.2019.00767

257. Wang J, Deng Q, Jiang YY, Zhang R, Zhu HB, Meng JX, et al. CAR-T 19 Combined With Reduced-Dose PD-1 Blockade Therapy for Treatment of Refractory Follicular Lymphoma: A Case Report. *Oncol Lett* (2019) 18 (5):15–20. doi: 10.3892/ol.2019.9182

258. Song W, Zhang M. Use of CAR-T Cell Therapy, PD-1 Blockade, and Their Combination for the Treatment of Hematological Malignancies. *Clin Immunol* (2020) 214:108382. doi: 10.1016/j.clim.2020.108382

259. John LB, Kershaw MH, Darcy PK. Blockade of PD-1 Immunosuppression Boosts CAR T-Cell Therapy. *Oncoimmunology* (2013) 2(10):e26286. doi: 10.4161/onci.26286

260. Zhang R, Deng Q, Jiang YY, Zhu HB, Wang J, Zhao MF. Effect and Changes in PD-1 Expression of CD19 CAR-T Cells From T Cells Highly Expressing PD-1 Combined With Reduced-Dose PD-1 Inhibitor. *Oncol Rep* (2019) 41 (6):3455–63. doi: 10.3822/or.2019.7096

261. Rafiq S, Yoku OO, Jackson HJ, Pardoun TJJ, van Leeuwen DG, Drakes DJ, et al. Targeted Delivery of a PD-1-Blocking scFv by CAR-T Cells Enhances Anti-Tumor Efficacy In Vivo. *Nat Biotechnol* (2018) 36(9):847–56. doi: 10.1038/nbt.4195

262. Kenderian SS, Ruella M, Sheshtova O, Klinchinsky M, Kim M, Porter DL, et al. Identification of PD1 and TIM3 As Checkpoints That Limit Chimeric Antigen Receptor T Cell Efficacy in Leukemia. *Biol Blood Marrow Transplant* (2016) 22(3):519–21. doi: 10.1182/bbmt.2015.11.291

263. Wenthe J, Naseri S, Hellström AC, Wiklund HJ, Eriksson E, Loskog A. Immunosuppressive Oncolytic Virotherapy for Multiple Myeloma Targeting 4-1BB and/or CD40. *Cancer Gene Ther* (2020) 27(12):948–59. doi: 10.1038/s41417-020-01023-w

264. Alabanza LM, Xiong Y, Vu B, Webster B, Wu D, Hu P, et al. Armored BCMA CAR T Cells Eliminate Multiple Myeloma and Are Resistant to the Suppressive Effects of TGF-β. *Front Immunol* (2022) 13:832645. doi: 10.3389/fimmu.2022.832645

265. Yang Q, Hao J, Chi M, Wang Y, Xin B, Huang J, et al. Superior Antitumor Immunotherapy Efficacy of Kynureninase Modified CAR-T Cells Through Targeting Kynurenine Metabolism. *Oncoimmunology* (2022) 11(1):2055703.

266. Ruella M, Klinchinsky M, Kenderian SS, Sheshtova O, Zieber A, Kraft DO, et al. Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells. *Cancer Discov* (2017) 7:1154–67. doi: 10.1158/2159-8290.CD-16-0850

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Zhang, Zhu, Zhang, Chen and Xiao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.